Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Company Information
About this company
Key people
Anders Rylander
Chief Executive Officer, Director
Anders Moren
Chief Financial Officer
Henrik Winther
Senior Vice President - Business Development
Helle Fisker
Vice President - Commercial and Marketing
Hanna Ritzen
Vice President - Research & Development
Hector Tamburini
Head of US Laboratory Operations, Regulatory & Quality
Fredrik Alpsten
Independent Chairman of the Board
Annika Carlsson Berg
Independent Director
Cornelis Peters Bogerd
Independent Director
Marie-Louise Fjallskog
Independent Director
Maria Birgitte Holmlund
Independent Director
Click to see more
Key facts
- Shares in issue277.49m
- EPICBIOVIC B
- ISINSE0008613731
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 115.90m
- Employees24
- ExchangeStockholm Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.